Recent advances in immunotherapy for hepatocellular carcinoma

Treatment of hepatocellular carcinoma (HCC) is challenging as most patients are diagnosed at advanced stage with underlying chronic liver conditions. Conventional systemic chemotherapy has failed in HCC, and the clinical efficacy of FDA-approved molecular targeted agents such as sorafenib and lenvat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hepatobiliary & pancreatic diseases international 2021-12, Vol.20 (6), p.511-520
Hauptverfasser:	Khan, Abid Ali, Liu, Zhi-Kun, Xu, Xiao
Format:	Artikel
Sprache:	eng
Schlagworte:	Adoptive cellular therapy Antineoplastic Agents - therapeutic use Carcinoma, Hepatocellular - therapy Combination therapy Hepatocellular carcinoma Humans Immune checkpoint inhibitor Immune evasion Immunotherapy Liver Neoplasms - therapy Predictive biomarkers Sorafenib - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!